Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Galié, N.
Right arrow Articles by Branzi, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Galié, N.
Right arrow Articles by Branzi, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Pharmacological impact on right ventricular remodelling in pulmonary arterial hypertension

Nazzareno Galié*, Alessandra Manes, Massimiliano Palazzini, Luca Negro, Serena Romanazzi and Angelo Branzi

Institute of Cardiology, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy

* Corresponding author. Tel: +39 051 349858; fax: +39 051 344859. E-mail address: nazzareno.galie{at}unibo.it

The pathophysiologic mechanisms of pulmonary arterial hypertension (PAH) are initiated by the progressive obstructive changes of the pulmonary resistance vessels which lead to the increase of the afterload of the right ventricle (RV) that responds with functional and structural adaptations. The RV remodelling compensates for a variable period of time but ultimately may fail leading to heart failure and death. The depression of myocardial contractility seems to be one of the primary events in the progression of heart failure in a chronically overloaded RV. However, afterload mismatch remains the leading determinant of heart failure in patients with both PAH and chronic thrombo-embolic pulmonary hypertension. Different therapies induce a variable degree of reverse remodelling on the heart changes typical of PAH. The extent of this effect is strictly related to the reduction of RV afterload. The best results are observed in patients who underwent lung transplantation, pulmonary endoarterectomy and in vasoreactive subjects responders to chronic treatment with calcium channel blocking agents. The RV reverse remodelling effects of the new targeted therapies in non-vasoreactive PAH patients appear to be only mild to moderate.

Key Words: Hypertension • Pulmonary • Right ventricle • Heart failure • Echocardiography • Lung transplantation • Medical treatment


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.